NURIX THERAPEUTICS, INC. Variable Lease, Payment
NURIX THERAPEUTICS, INC. (NRIX) reported Variable Lease, Payment of $600.00 thousand for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:VariableLeasePayment · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. variable lease, payment for the quarter ending 2026-05-31 was $600.00K, a 53.85% decline year-over-year.
- NURIX THERAPEUTICS, INC. variable lease, payment for the quarter ending 2026-02-28 was $900.00K, a 52.63% decline year-over-year.
- NURIX THERAPEUTICS, INC. variable lease, payment for the quarter ending 2025-11-30 was $1.90M, a 5.56% increase year-over-year.
- NURIX THERAPEUTICS, INC. variable lease, payment for the quarter ending 2025-08-31 was $1.80M, a 0.00% change year-over-year.
- NURIX THERAPEUTICS, INC. variable lease, payment for fiscal 2025 was $6.90M, a 1.43% decline from fiscal 2024.
- NURIX THERAPEUTICS, INC. variable lease, payment for fiscal 2024 was $7.00M, a 12.90% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. variable lease, payment for fiscal 2023 was $6.20M, a 40.91% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. variable lease, payment for fiscal 2022 was $4.40M.
| Period end | Variable Lease, Payment 3 month | Variable Lease, Payment 6 month | Variable Lease, Payment 9 month | Variable Lease, Payment 12 month |
|---|---|---|---|---|
| 2026-05-31 | $600.00K 10-Q · filed 2026-07-09 | $1.60M 10-Q · filed 2026-07-09 | $3.40M derived: sum of 3 quarters · filed 2026-07-09 | $5.20M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $900.00K 10-Q · filed 2026-04-08 | $2.80M derived: sum of 2 quarters · filed 2026-04-08 | $4.60M derived: sum of 3 quarters · filed 2026-04-08 | $5.90M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.70M derived: sum of 2 quarters · filed 2026-01-28 | $5.00M derived: sum of 3 quarters · filed 2026-07-09 | $6.90M 10-K · filed 2026-01-28 |
| 2025-08-31 | $1.80M 10-Q · filed 2025-10-09 | $3.10M derived: sum of 2 quarters · filed 2026-07-09 | $5.00M 10-Q · filed 2025-10-09 | $6.80M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $1.30M 10-Q · filed 2026-07-09 | $3.20M 10-Q · filed 2026-07-09 | $5.00M derived: sum of 3 quarters · filed 2026-07-09 | $6.80M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $1.90M 10-Q · filed 2026-04-08 | $3.70M derived: sum of 2 quarters · filed 2026-04-08 | $5.50M derived: sum of 3 quarters · filed 2026-04-08 | $7.30M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.60M derived: sum of 2 quarters · filed 2026-01-28 | $5.40M derived: sum of 3 quarters · filed 2026-01-28 | $7.00M 10-K · filed 2026-01-28 |
| 2024-08-31 | $1.80M 10-Q · filed 2025-10-09 | $3.60M derived: sum of 2 quarters · filed 2025-10-09 | $5.20M 10-Q · filed 2025-10-09 | $6.70M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $1.80M 10-Q · filed 2025-07-09 | $3.30M 10-Q · filed 2025-07-09 | $4.90M derived: sum of 3 quarters · filed 2026-01-28 | $6.50M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $1.50M 10-Q · filed 2025-04-08 | $3.10M derived: sum of 2 quarters · filed 2026-01-28 | $4.70M derived: sum of 3 quarters · filed 2026-01-28 | $6.50M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.20M derived: sum of 2 quarters · filed 2026-01-28 | $5.00M derived: sum of 3 quarters · filed 2026-01-28 | $6.20M 10-K · filed 2026-01-28 |
| 2023-08-31 | $1.60M 10-Q · filed 2024-10-11 | $3.40M derived: sum of 2 quarters · filed 2024-10-11 | $4.60M 10-Q · filed 2024-10-11 | |
| 2023-05-31 | $1.80M 10-Q · filed 2024-07-11 | $3.10M 10-Q · filed 2024-07-11 | ||
| 2023-02-28 | $1.20M 10-Q · filed 2024-04-10 | |||
| 2022-11-30 | $4.40M 10-K · filed 2025-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |